Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5615233 | Journal of Clinical Lipidology | 2017 | 9 Pages |
Abstract
After reporting of the neutral ENHANCE results, ezetimibe discontinuation rate increased, LDL-C levels increased, and predicted CVD risk increased among those who discontinued ezetimibe. Characterization of clinical outcomes regarding lipid-altering agents based on surrogate biomarker studies not designed to assess CVD outcomes may be misleading, potentially placing patients at increased CVD risk.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Harold E. MD, Mehul D. PhD, Panagiotis PhD, Dena R. BA, Joanne E. PhD, Andrew M. MD, MPH, Carl A. PhD,